Cencora, Inc, based in Pennsylvania-based Conshohocken. (COR) Pharmaceutical sources and distribution. Valued by market capitalization of $58.7 billion, the company provides end-to-end pharmaceutical commercialization solutions, over-the-counter healthcare products, home health supplies and equipment, and related services to healthcare providers.
Companies worth more than $10 billion are commonly referred to as “large caps.” Cor fits the bill easily, with market capitalization exceeding this mark, highlighting its size, influence and advantage in the health distribution industry. Cencora's strengths stem from its strategic position in healthcare value chains, diverse portfolios and scale-driven negotiation power. Develop innovation and operational excellence by leveraging cross-business synergies, strong brand equity and a healthy balance sheet. With its technical capabilities in supply chain management and data analytics, Cencora offers high operational efficiency, consistently achieving fill rates above 99%, tailoring industry trends such as value-based care and personalized healthcare.
Despite its remarkable strength, Cor slid 2.2% from $309.35 from its 52-week high achieved on May 7th. Over the past three months, COR stocks have earned 2.5%, surpassing the 1% increase in Healthcare Select Sector SPDR Fund (XLV) over the same time frame.
In the long term, Cor Rose stock was 34.6% on a YTD basis, up 27.3% over the last 52 weeks, surpassing XLV's YTD marginal profits and exceeding 11.4% DIP last year.
To confirm bullish trends, COR has traded above the 200-day moving average of the past year, with some fluctuations. Stocks have been trading above the 50-day moving average starting in mid-October 2024, with some fluctuations.
Cencora announced its third quarter results on August 6, surpassing expectations, up 8.7% year-on-year to $80.7 billion, up 19.8% from the Ago-AGO quarter. The company also raised its adjusted EPS guidance for 2025 from $15.85 to $16. Despite its strong performance, Cencora stock fell 2.9% after earnings announcement.
The story continues
